title: Pediatric undifferentiated sarcoma of the soft tissues: a clinicopathologic study.
abstract: Pediatric undifferentiated soft tissue sarcomas represent a major challenge for pathologists and clinicians. The goal of this study was to identify cases that warranted this diagnosis by current standards of analysis and then determine if there are clinicopathological commonalities that may be useful for diagnosis, management, and prognosis. Eighteen potential patients were identified using the institutional pathology database. Three cases were reclassified as specific sarcomas, and 2 cases had insufficient material for molecular analysis, leaving 13 cases for pathological review and 12 patients for radiological and clinical review. There were 7 males and 6 females. The median age at diagnosis was 11 years (1 month to 16 years). Tumors commonly involved the trunk (7 of 13; 54%) and ranged in size from 1.7 to 14.5 cm (mean, 6.7 cm). Eleven patients received ifosfamide/etoposide chemotherapy and 4 received irradiation. Five-year event-free and overall survival (EFS and OS) rates were 54% and 74%, respectively. The predominant histological pattern was round to plump spindled cells forming sheets (9 of 13; 69%) and severe atypia was associated with decreased survival (P = 0.048). Immunohistochemistry showed positivity for vimentin (92%), CD117 (92%), and vascular endothelial growth factor (69%), and 8% to 23% showed focal positivity for epithelial, neural, or myogenic markers. Tumors were uniformly negative for translocations associated with pediatric sarcomas. The presence of certain common morphological and immunohistochemical features in the absence of specific molecular genetic abnormalities allows for a diagnosis of pediatric undifferentiated soft tissue sarcoma; however, whether this group of neoplasms forms a unique category of tumors or a common precursor pathway for a number of different sarcomas awaits further study.
authors.affiliation: Division of Pathology, Hospital for Sick Children, 555 University Avenue, Toronto, ON M5G 1X8, Canada. gino.somers@sickkids.ca
authors.forename: Gino R
authors.initials: GR
authors.lastname: Somers
authors.forename: Abha A
authors.initials: AA
authors.lastname: Gupta
authors.forename: Andrea S
authors.initials: AS
authors.lastname: Doria
authors.forename: Michael
authors.initials: M
authors.lastname: Ho
authors.forename: Carlos
authors.initials: C
authors.lastname: Pereira
authors.forename: Mary
authors.initials: M
authors.lastname: Shago
authors.forename: Paul S
authors.initials: PS
authors.lastname: Thorner
authors.forename: Maria
authors.initials: M
authors.lastname: Zielenska
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D015870:Gene Expression; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007223:Infant; D008297:Male; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000032:analysis; D011878:Radiotherapy; D012189:Retrospective Studies; D012509:Sarcoma / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012983:Soft Tissue Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D046888:Tissue Array Analysis
chemical_list: D012333:RNA, Messenger; D012334:RNA, Neoplasm; D005047:Etoposide; D007069:Ifosfamide